.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX75_Tebentafusp.Tebentafusp .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX75_Tebentafusp.Tebentafusp| name: | Tebentafusp | |
| ATC code: | L01XX75 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 68 | mg |
| volume of distribution: | 2.63 | L |
| clearance: | 0.043 | L/h |
| other parameters in model implementation | ||
Tebentafusp is a bispecific fusion protein that targets glycoprotein 100 (gp100)-positive cells by redirecting T cells to recognize and destroy uveal melanoma cells. It is approved for the treatment of unresectable or metastatic uveal melanoma in adults.
Population pharmacokinetics in adult patients with metastatic uveal melanoma; both sexes; typical clinical dosing regimen.